FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985763670> ?p ?o ?g. }

• W1985763670 endingPage "1939" @default.
• W1985763670 startingPage "1932" @default.
• W1985763670 abstract "Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.In an international double-blind placebo-controlled phase III clinical trial, 428 patients who had active rheumatoid arthritis, who had received continuous methotrexate for at least 3 months and at a stable dose for at least 4 weeks, were randomised to placebo (n=88) or one of four regimens of infliximab at weeks 0, 2, and 6. Additional infusions of the same dose were given every 4 or 8 weeks thereafter on a background of a stable dose of methotrexate (median 15 mg/week for > or =6 months, range 10-35 mg/wk). Patients were assessed every 4 weeks for 30 weeks.At 30 weeks, the American College of Rheumatology (20) response criteria, representing a 20% improvement from baseline, were achieved in 53, 50, 58, and 52% of patients receiving 3 mg/kg every 4 or 8 weeks or 10 mg/kg every 4 or 8 weeks, respectively, compared with 20% of patients receiving placebo plus methotrexate (p<0.001 for each of the four infliximab regimens vs placebo). A 50% improvement was achieved in 29, 27, 26, and 31% of infliximab plus methotrexate in the same treatment groups, compared with 5% of patients on placebo plus methotrexate (p<0.001). Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.During 30 weeks, treatment with infliximab plus methotrexate was more efficacious than methotrexate alone in patients with active rheumatoid arthritis not previously responding to methotrexate." @default.
• W1985763670 created "2016-06-24" @default.
• W1985763670 creator A5013156684 @default.
• W1985763670 creator A5018678002 @default.
• W1985763670 creator A5025407380 @default.
• W1985763670 creator A5030335777 @default.
• W1985763670 creator A5043874873 @default.
• W1985763670 creator A5046048546 @default.
• W1985763670 creator A5052078671 @default.
• W1985763670 creator A5055845716 @default.
• W1985763670 creator A5057580992 @default.
• W1985763670 creator A5063329660 @default.
• W1985763670 creator A5090753435 @default.
• W1985763670 date "1999-12-01" @default.
• W1985763670 modified "2023-10-09" @default.
• W1985763670 title "Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial" @default.
• W1985763670 cites W1973123086 @default.
• W1985763670 cites W1983145703 @default.
• W1985763670 cites W1996472975 @default.
• W1985763670 cites W2018456421 @default.
• W1985763670 cites W2026342001 @default.
• W1985763670 cites W2043287930 @default.
• W1985763670 cites W2081734937 @default.
• W1985763670 cites W2088309088 @default.
• W1985763670 cites W2098767548 @default.
• W1985763670 cites W2101840353 @default.
• W1985763670 cites W2136430968 @default.
• W1985763670 cites W2142273705 @default.
• W1985763670 cites W2143939606 @default.
• W1985763670 cites W2158006783 @default.
• W1985763670 cites W2159106700 @default.
• W1985763670 cites W2314052274 @default.
• W1985763670 cites W2320562573 @default.
• W1985763670 cites W2326789779 @default.
• W1985763670 cites W2328587823 @default.
• W1985763670 doi "https://doi.org/10.1016/s0140-6736(99)05246-0" @default.
• W1985763670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10622295" @default.
• W1985763670 hasPublicationYear "1999" @default.
• W1985763670 type Work @default.
• W1985763670 sameAs 1985763670 @default.
• W1985763670 citedByCount "2234" @default.
• W1985763670 countsByYear W19857636702012 @default.
• W1985763670 countsByYear W19857636702013 @default.
• W1985763670 countsByYear W19857636702014 @default.
• W1985763670 countsByYear W19857636702015 @default.
• W1985763670 countsByYear W19857636702016 @default.
• W1985763670 countsByYear W19857636702017 @default.
• W1985763670 countsByYear W19857636702018 @default.
• W1985763670 countsByYear W19857636702019 @default.
• W1985763670 countsByYear W19857636702020 @default.
• W1985763670 countsByYear W19857636702021 @default.
• W1985763670 countsByYear W19857636702022 @default.
• W1985763670 countsByYear W19857636702023 @default.
• W1985763670 crossrefType "journal-article" @default.
• W1985763670 hasAuthorship W1985763670A5013156684 @default.
• W1985763670 hasAuthorship W1985763670A5018678002 @default.
• W1985763670 hasAuthorship W1985763670A5025407380 @default.
• W1985763670 hasAuthorship W1985763670A5030335777 @default.
• W1985763670 hasAuthorship W1985763670A5043874873 @default.
• W1985763670 hasAuthorship W1985763670A5046048546 @default.
• W1985763670 hasAuthorship W1985763670A5052078671 @default.
• W1985763670 hasAuthorship W1985763670A5055845716 @default.
• W1985763670 hasAuthorship W1985763670A5057580992 @default.
• W1985763670 hasAuthorship W1985763670A5063329660 @default.
• W1985763670 hasAuthorship W1985763670A5090753435 @default.
• W1985763670 hasConcept C126322002 @default.
• W1985763670 hasConcept C141071460 @default.
• W1985763670 hasConcept C142724271 @default.
• W1985763670 hasConcept C17991360 @default.
• W1985763670 hasConcept C198451711 @default.
• W1985763670 hasConcept C204787440 @default.
• W1985763670 hasConcept C27081682 @default.
• W1985763670 hasConcept C2777077863 @default.
• W1985763670 hasConcept C2777138892 @default.
• W1985763670 hasConcept C2777575956 @default.
• W1985763670 hasConcept C2779384505 @default.
• W1985763670 hasConcept C2781059491 @default.
• W1985763670 hasConcept C71924100 @default.
• W1985763670 hasConcept C90924648 @default.
• W1985763670 hasConceptScore W1985763670C126322002 @default.
• W1985763670 hasConceptScore W1985763670C141071460 @default.
• W1985763670 hasConceptScore W1985763670C142724271 @default.
• W1985763670 hasConceptScore W1985763670C17991360 @default.
• W1985763670 hasConceptScore W1985763670C198451711 @default.
• W1985763670 hasConceptScore W1985763670C204787440 @default.
• W1985763670 hasConceptScore W1985763670C27081682 @default.
• W1985763670 hasConceptScore W1985763670C2777077863 @default.
• W1985763670 hasConceptScore W1985763670C2777138892 @default.
• W1985763670 hasConceptScore W1985763670C2777575956 @default.
• W1985763670 hasConceptScore W1985763670C2779384505 @default.
• W1985763670 hasConceptScore W1985763670C2781059491 @default.
• W1985763670 hasConceptScore W1985763670C71924100 @default.
• W1985763670 hasConceptScore W1985763670C90924648 @default.
• W1985763670 hasIssue "9194" @default.
• W1985763670 hasLocation W19857636701 @default.
• W1985763670 hasLocation W19857636702 @default.
• W1985763670 hasOpenAccess W1985763670 @default.
• W1985763670 hasPrimaryLocation W19857636701 @default.

• next